Where are you?
To give you the most accurate information about our products and what we can do for you, we need to direct you to the right site.
Kuros Biosciences is on a mission to discover, develop and deliver innovative fusion technologies that prevent non-unions.
Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange (Ticker: KURN) since 2016. With operations in the Netherlands and the USA, we employ a growing team of 75 people.
To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to reduce spinal fusion failure rates. Our credentials:
Find out more about Kuros and meet our team at one of these upcoming events.
12 Jan 2024
Grand Hyatt Vail, Colorado
25 Jan 2024
White Sulfer Springs, West Virginia
07 Feb 2024
Deer Valley, Utah
Completed Fibrin-PTH (KUR-113) Phase 2 clinical trial enrollment
US HQ moved to Atlanta
US office opened in Boston
First human data for MagnetOs published
Launch of MagnetOs in nine European countries
Signing of first APAC disributor
First patient treated with MagnetOs (US)
US Registration and virtual office established
Acquired Xpand Biotechnology in 2017
to strengthen the biologics platform
Listed on Swiss Exchange
Founded as a spin-off of Swiss Federal Institute of Technology in Zurich